"Survival analyses conducted in an ancillary study of the RACE trial (https://clinicaltrials.gov/ct2/show/NCT01665092) of patients that received either L-carnitine (18g dose) or placebo using a range of pre-treatment serum acetylcarnitine and valine concentrations as measured by LC-MS or NMR, respectively"


CSV files: represent the number of at risk subjects for each representative Kaplan Meier analysis (pdf) for each acetylcarnitine (LC-MS) or valine (NMR) concentration scenario (including one for all patients) for patients that received either L-carnitine (18g) or placebo

CSV file name: SA-at risk L-carnitine 18g v PL acetylcarnitine- all pts: represents the at risk subjects at various time points that received either L-carnitine (18g) or placebo

CSV file name: SA-at risk 35然 L-carnitine 18g v PL acetylcarnitine: represents the at risk subjects at various time points that received either L-carnitine (18g) or placebo that had pre-treatment serum acetylcarnitine concentrations of 35然 or above

CSV file name: SA-at risk 30然 L-carnitine 18g v PL acetylcarnitine: represents the at risk subjects at various time points that received either L-carnitine (18g) or placebo that had pre-treatment serum acetylcarnitine concentrations of 30然 or above

CSV file name: SA-at risk 21然 L-carnitine 18g v PL acetylcarnitine: represents the at risk subjects at various time points that received either L-carnitine (18g) or placebo that had pre-treatment serum acetylcarnitine concentrations of 21然 or above

CSV file name: SA-at risk L-carnitine 18g v PL valine- all pts: represents the at risk subjects at various time points that received either L-carnitine (18g) or placebo 

CSV file name: SA-at risk 88然 L-carnitine 18g v PL valine: represents the at risk subjects at various time points that received either L-carnitine (18g) or placebo that had pre-treatment serum valine concentrations of 88然 or above

CSV file name: SA-at risk 75然 L-carnitine 18g v PL valine: represents the at risk subjects at various time points that received either L-carnitine (18g) or placebo that had pre-treatment serum valine concentrations of 75然 or above

CSV file name: SA-at risk 60然 L-carnitine 18g v PL valine: represents the at risk subjects at various time points that received either L-carnitine (18g) or placebo that had pre-treatment serum valine concentrations of 60然 or above


PDF files: show the results of the survival analysis for each acetylcarnitine (LC-MS) or valine (NMR) pre-treatment concentration scenario as well as one for all patients that received either L-carnitine (18g) or placebo including the associated statistical analysis

PDF name: SA-acylcarnitines-all subjects: shows the survival analysis results for patients that received either L-carnitine (18g) or placebo for which acylcarnitine data were obtained

PDF name: SA-acetylcarnitine-21然: shows the survival analysis results for patients that received either L-carnitine (18g) or placebo that had pretreatment serum concentrations of 21然 or above

PDF name: SA-acetylcarnitine-30然: shows the survival analysis results for patients that received either L-carnitine (18g) or placebo that had pretreatment serum concentrations of 30然 or above

PDF name: SA-acetylcarnitine-35uM: shows the survival analysis results for patients that received either L-carnitine (18g) or placebo that had pretreatment serum concentrations of 35然 or above

PDF name: SA-NMR data-all subjects: shows the survival analysis results for patients that received either L-carnitine (18g) or placebo for which NMR data were obtained

PDF name: SA-NMR data-valine-60然: shows the survival analysis results for patients that received either L-carnitine (18g) or placebo that had pretreatment serum concentrations of 60然 or above

PDF name: SA-NMR data-valine-75然: shows the survival analysis results for patients that received either L-carnitine (18g) or placebo that had pretreatment serum concentrations of 75然 or above

PDF name: SA-NMR data-valine-88然: shows the survival analysis results for patients that received either L-carnitine (18g) or placebo that had pretreatment serum concentrations of 88然 or above